Mucinous ovarian carcinomas are associated with the copy number loss of CDKN2A and KRAS mutations, both of which are believed to be early events in tumorigenesis as they have been identified in benign and borderline mucinous precursor neoplasms [15,16]. The gene discussed is KRAS; the disease is ovarian mucinous adenocarcinoma.